Q4 2023 Earnings Estimate for Prestige Consumer Healthcare Inc. (NYSE:PBH) Issued By Jefferies Financial Group

Prestige Consumer Healthcare Inc. (NYSE:PBHGet Rating) – Stock analysts at Jefferies Financial Group upped their Q4 2023 earnings per share (EPS) estimates for Prestige Consumer Healthcare in a note issued to investors on Tuesday, May 10th. Jefferies Financial Group analyst S. Wissink now forecasts that the company will post earnings per share of $1.06 for the quarter, up from their previous forecast of $1.04. Jefferies Financial Group has a “Buy” rating and a $70.00 price objective on the stock.

A number of other equities research analysts also recently commented on the stock. StockNews.com started coverage on shares of Prestige Consumer Healthcare in a research report on Thursday, March 31st. They issued a “buy” rating for the company. Oppenheimer upgraded shares of Prestige Consumer Healthcare from a “market perform” rating to an “outperform” rating and set a $63.00 price target on the stock in a research note on Monday. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $76.40.

NYSE:PBH opened at $55.63 on Thursday. The company has a current ratio of 2.04, a quick ratio of 1.25 and a debt-to-equity ratio of 1.01. Prestige Consumer Healthcare has a 12 month low of $46.31 and a 12 month high of $63.83. The company has a market cap of $2.79 billion, a PE ratio of 13.77, a price-to-earnings-growth ratio of 1.60 and a beta of 0.58. The company has a 50 day simple moving average of $54.62 and a two-hundred day simple moving average of $57.72.

Prestige Consumer Healthcare (NYSE:PBHGet Rating) last posted its earnings results on Thursday, May 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.02. Prestige Consumer Healthcare had a net margin of 18.90% and a return on equity of 14.08%. The business had revenue of $266.94 million during the quarter, compared to the consensus estimate of $258.25 million. During the same quarter in the previous year, the firm posted $0.79 EPS. The firm’s revenue was up 12.3% on a year-over-year basis.

Several institutional investors have recently modified their holdings of PBH. Allspring Global Investments Holdings LLC purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth $70,754,000. Norges Bank purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at $28,499,000. Leeward Investments LLC MA purchased a new position in shares of Prestige Consumer Healthcare during the 1st quarter valued at $20,281,000. Goldman Sachs Group Inc. lifted its stake in shares of Prestige Consumer Healthcare by 50.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 702,442 shares of the company’s stock valued at $42,603,000 after buying an additional 236,496 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 598.5% during the 3rd quarter. Millennium Management LLC now owns 237,243 shares of the company’s stock valued at $13,312,000 after buying an additional 203,276 shares in the last quarter.

About Prestige Consumer Healthcare (Get Rating)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Further Reading

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.